According to the Zhitong Finance APP, Science Sun Pharm (300485.SZ) released its performance forecast for 2024, expecting a net loss attributable to shareholders of the listed company of between 59.1728 million yuan and 88.7592 million yuan, a year-on-year shift from profit to loss.

During the reporting period, the company recognized a decrease in the fair value changes of financial assets and investment income from joint ventures in accordance with the new financial instruments standards compared to the previous period. The company's invested financial assets are mainly in biomedicine, medical devices, and other companies related to its main business, as well as specialized investment funds in the pharmaceutical and health sectors. The fair value change income and investment income for this reporting period is approximately -110 million yuan, representing a decline of about 170%